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ABSTRACT 26	
Several conditions associated with reduced gastric acid secretion confer an altered 27	
risk of developing a gastric malignancy. Helicobacter pylori-induced atrophic gastritis 28	
predisposes to gastric adenocarcinoma, autoimmune atrophic gastritis is a precursor 29	
of type I gastric neuroendocrine tumours, whereas proton pump inhibitor (PPI) use 30	
does not affect stomach cancer risk. We hypothesised that each of these conditions 31	
was associated with specific alterations in the gastric microbiota and that this 32	
influenced subsequent tumour risk. 95 patients (in groups representing normal 33	
stomach, PPI treated, H. pylori gastritis, H. pylori-induced atrophic gastritis and 34	
autoimmune atrophic gastritis) were selected from a cohort of 1400. RNA extracted 35	
from gastric corpus biopsies was analysed using 16S rRNA sequencing (MiSeq). 36	
Samples from normal stomachs and patients treated with PPIs demonstrated 37	
similarly high microbial diversity. Patients with autoimmune atrophic gastritis also 38	
exhibited relatively high microbial diversity, but with samples dominated by 39	
Streptococcus. H. pylori colonisation was associated with decreased microbial 40	
diversity and reduced complexity of co-occurrence networks. H. pylori-induced 41	
atrophic gastritis resulted in lower bacterial abundances and diversity, whereas 42	
autoimmune atrophic gastritis resulted in greater bacterial abundance and equally 43	
high diversity compared to normal stomachs. Pathway analysis suggested that 44	
glucose-6-phospahte1-dehydrogenase and D-lactate dehydrogenase were over 45	
represented in H. pylori-induced atrophic gastritis versus autoimmune atrophic 46	
gastritis, and that both these groups showed increases in fumarate reductase. 47	
Autoimmune and H. pylori-induced atrophic gastritis were associated with different 48	
gastric microbial profiles. PPI treated patients showed relatively few alterations in the 49	
gastric microbiota compared to healthy subjects. 50	
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AUTHOR SUMMARY 51	
Different conditions such as autoimmune atrophic gastritis and Helicobacter pylori 52	
associated atrophic gastritis are associated with different types of gastric cancer, 53	
specifically neuroendocrine tumours and adenocarcinoma. Both conditions result in 54	
reduced gastric acid secretion, potentially allowing non-H. pylori bacteria to colonise 55	
the stomach. However patients receiving proton pump inhibitors (PPI) experience 56	
similar levels of acid secretion, but do not develop gastric cancer. The aims of this 57	
study were to investigate the contribution of non-H. pylori microbiota to gastric 58	
tumour development in the presence of reduced gastric acid secretion and controls.  59	
16S rRNA sequencing identified relatively few alterations in the gastric microbiota in 60	
patients receiving PPI therapy, despite reduced acid secretion, but more substantial 61	
alterations in those patents who had atrophic gastritis. Significant differences were 62	
also found between the patients who had atrophic gastritis of autoimmune and H. 63	
pylori associated types. Differences in biochemical pathways that potentially 64	
contribute to gastric tumorigenesis were also predicted. 65	
This work increases understanding of the mechanisms involved in gastric tumour 66	
development, and demonstrates how non-H. pylori bacteria may be important. This 67	
work may eventually lead to the development of novel chemopreventive therapies for 68	
stomach cancer that are based on altering the composition of the gastric microbiota. 69	
  70	
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INTRODUCTION 71	
Gastric adenocarcinoma is the third most common cause of cancer related mortality 72	
worldwide[1] and most cases are associated with chronic Helicobacter pylori 73	
infection. Gastric cancer usually develops via the premalignant condition of gastric 74	
atrophy, which is associated with the loss of acid-secreting parietal cells[2]. The 75	
resulting hypochlorhydria potentially leads to alterations in the composition of the 76	
gastric microbiota by providing a more favourable environment for colonisation. It is 77	
currently unclear to what extent the non-H. pylori gastric microbiota contributes 78	
towards gastric carcinogenesis. Although the hypochlorhydria associated with 79	
autoimmune atrophic gastritis also increases the risk of developing gastric 80	
adenocarcinoma[3], it is more frequently associated with the development of another 81	
tumour, the type I gastric neuroendocrine tumour (NET)[4]. However, 82	
hypochlorhydria does not always increase the risk of gastric tumour development, as 83	
observed following chronic proton pump inhibitor (PPI) use[5]. Therefore, factors in 84	
addition to hypochlorhydria affect gastric cancer risk and one of these could be the 85	
gastric microbiota. 86	
Although originally thought to be sterile, several bacterial communities have been 87	
shown to survive in the normal human stomach[6]. Differences have also been 88	
observed depending upon H. pylori status[6].There is now overwhelming evidence 89	
that certain bacteria influence cancer development. Potential mechanisms include 90	
altering the host immune system, exacerbating inflammation, or converting dietary 91	
nitrates to produce carcinogens such as N-nitrosamines and nitric oxide[7-13].  92	
We therefore hypothesised that three stimuli which result in hypochlorhydria, namely 93	
H. pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump 94	
inhibitor use cause specific changes to the composition of the gastric microbiota. In 95	
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addition, the gastric microbiota that is present in these conditions contributes 96	
towards the specific gastric tumour risk that is associated with each of these 97	
hypochlorhydric states. We have used 16S rRNA sequencing to determine the 98	
gastric mucosal microbiota profiles in patients with these causes of hypochlorhydria 99	
and have compared these with samples obtained from healthy subjects and from 100	
patients with H. pylori-induced gastritis, but no evidence of gastric atrophy.    101	
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RESULTS 102	
Patient characteristics 103	
Patients were selected from the larger cohort according to criteria defined in the 104	
methods section and Table 1. Characteristics of the selected patients are shown in 105	
table 1 and figure 1A. One sample from the normal stomach group and four from the 106	
PPI-treated group were subsequently excluded because sequencing showed the 107	
presence of >15% H. pylori despite this organism being undetected by conventional 108	
clinical tests (most likely due to the higher sensitivity of 16S rRNA sequencing 109	
compared to routine clinical tests). This is likely to be genuine H. pylori carriage 110	
since technical controls were included in each sequencing run and these controls 111	
showed lower diversity and levels of H. pylori than the samples (Figs 2 & 3). Ninety-112	
five samples were therefore analysed. Negative extracts from the RNA extraction 113	
procedures, a water sample in the first PCR and a mock bacterial community were 114	
also sequenced.  115	
 116	
Detection of Operational Taxonomic Units (OTUs) 117	
In total 10,386 OTUs were identified. Extraction controls contained fewer OTUs than 118	
the patient samples, whilst the mock communities showed consistency between 119	
MiSeq runs (Figs 1-3). Despite the negative extracts being theoretically sterile, as 120	
expected they generated 16S signals due to known background reagent 121	
contamination[14]. Samples from the autoimmune atrophic gastritis group contained 122	
the largest number of OTUs, whilst all other patient groups were comparable (Fig 123	
1B). Mock communities demonstrated the expected bacterial ratios (Fig 3B). 124	
 125	
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Bacterial diversity and abundance in the different hypochlorhydric states 126	
Twenty-three known phyla were identified, mainly Proteobacteria, Firmicutes, 127	
Bacteroidetes, Actinobacteria, Fusobacteria and Cyanobacteria. Bacteroidetes, 128	
followed by Proteobacteria and Firmicutes were most common in normal stomachs, 129	
whereas samples from PPI-treated patients contained slightly more Firmicutes and 130	
fewer Bacteroidetes. The H. pylori gastritis and H. pylori atrophic gastritis samples 131	
were dominated by Proteobacteria (as Helicobacter itself is a member of this 132	
phylum), whilst biopsies from patients with autoimmune atrophic gastritis contained 133	
the largest proportion of Firmicutes compared to all other patient groups.  134	
Alpha diversity  135	
Diversity indices demonstrated that the microbiota in normal stomachs was 136	
significantly more diverse than in the stomachs of all other patient groups except for 137	
the patients who had autoimmune atrophic gastritis (Fig 2, all panels). Evaluation of 138	
evenness (by Pielou’s evenness and Simpson) suggested that the samples from 139	
normal stomachs and from the stomachs of patients taking PPIs contained bacterial 140	
communities that were more equal in abundance than those in the other patient 141	
groups, which were more skewed (Fig 2). Calculations based on richness indicated 142	
that the samples from normal stomachs also contained the greatest number of 143	
different bacterial species compared to all other groups, whilst the two H. pylori 144	
infected groups (H. pylori-induced gastritis and atrophy) contained significantly fewer 145	
species. 146	
 147	
Beta diversity 148	
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When beta diversity was explored using nonmetric distance scaling (NMDS), patient 149	
groups clustered predominantly by bacterial abundance (Fig 4). When H. pylori was 150	
removed from the analysis however, H. pylori gastritis patients no longer clustered 151	
separately by abundance from subjects with normal stomachs (Fig 4). Despite this, 152	
following removal of H. pylori, there was a significant difference in abundance for H. 153	
pylori-induced atrophic gastritis patients compared to normal stomachs, suggesting 154	
strongly that there are differences in the proportions of non-H. pylori bacteria in these 155	
subjects compared with others (Fig 4). Samples from patients who had autoimmune 156	
atrophic gastritis displayed the only significant differences in terms of the presence 157	
or absence of specific bacteria compared to other groups (Fig 4). This suggests that 158	
changes in the gastric bacterial community during hypochlorhydria usually involve 159	
changes in the relative proportions of bacteria that are already present, and only 160	
rarely involve the loss or gain of specific bacterial genera. 161	
 162	
Comparisons between the microbiota profiles in the different patient groups 163	
and healthy controls 164	
Normal stomach versus PPI treated patients 165	
Patients receiving PPIs showed similar bacterial profiles to those found in the 166	
stomachs of normal subjects, despite having significantly higher serum gastrin 167	
concentrations (suggesting the presence of hypochlorhydria) (Figs 1A, 3 & S1). 168	
Nonetheless there were differences in the ranks of most abundant bacterial families. 169	
In normal (control) patients Prevotellaceae were the most abundant bacterial family 170	
(23%), followed by Streptococcaceae (10%), Paraprevotellaceae (7%) and 171	
Fusobacteriaceae (5%); amongst PPI-treated individuals Streptococcaceae (17%) 172	
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outranked Prevotellaceae (11%), Campylobacteraceae (5%) and Leptotrichiaceae 173	
(4%; Fig 3A). The only significant differences at genus level between these groups 174	
were decreases in Actinobacillus and Tannerella in the PPI-treated stomachs (Table 175	
S1). At the OTU level, Cyanobacteria, and Streptococcus were significantly 176	
increased in the PPI-treated samples, whereas Prevotella, Porphyromonas, 177	
Treponema, Leptotrichiaceae, Haemophilus, and Fusobacterium were significantly 178	
decreased compared to normal stomachs (Fig S2).  179	
Very few differences were identified in co-occurrence network analyses when the 180	
microbiota in normal stomachs was compared to PPI-treated stomachs. The only 181	
observed difference was a negative correlation between Helicobacter and 182	
Acinetobacter in the PPI-treated samples, whereas this relationship was positively 183	
correlated in normal stomach biopsies (Figs 5A, S3A & Table S2A). Predicted 184	
pathway analysis showed no significantly different biochemical pathways between 185	
these two groups (Table S3).  186	
 187	
Normal stomach versus H. pylori-induced gastritis 188	
Unsurprisingly, the microbiota in the stomachs of patients who had H. pylori-induced 189	
gastritis consisted almost entirely of Helicobacteraceae (97%) (Fig 3). When 190	
compared to normal patients, H. pylori-induced gastritis patients showed a greater 191	
number of differences at the genus level than all other patient groups (Table S1). 192	
The majority of these differences resulted from reductions in the proportions of 193	
several bacterial genera within the H. pylori gastritis group. To ensure that the 194	
dominance of H. pylori did not skew the proportions of the other bacteria in a 195	
misrepresentational way, H. pylori OTUs were removed from the abundance table 196	
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followed by differential expression analysis on the remaining raw abundances. This 197	
analysis resulted in almost identical results to when H. pylori remained (Table S1). 198	
Due to the dominance of H. pylori in these patients, very few co-occurrence networks 199	
were identified, but positive correlations were observed between Kocuria and 200	
Skermanella in both groups (Figs 5A & B). Predicted pathway analysis suggested a 201	
reduction in several dehydrogenases in the stomachs of patients who had H. pylori 202	
gastritis (Table S3).  203	
 204	
Normal stomach versus H. pylori-induced atrophic gastritis 205	
The stomachs of patients who had H. pylori-induced atrophic gastritis were also 206	
dominated by Helicobacteraceae (62%), followed by Streptococcaceae (5%), 207	
Fusobacteriaceae (2%) and Prevotellaceae (2%) (Fig 3). At the genus level, several 208	
differences were observed between normal stomachs and the stomachs of patients 209	
with H. pylori-induced atrophic gastritis. These included decreases in the proportions 210	
of Tannerella (E. coli/Shigella/Salmonella, see supplementary methods), 211	
Treponema, and Prevotella in the H. pylori-induced atrophic gastritis group. The vast 212	
majority of these differences remained when H. pylori was removed from the 213	
analysis (Table S1). Prevotellaceae were generally lower in all patient groups 214	
compared to normal stomachs (Figs S1 and 3). As with the H. pylori gastritis group, 215	
the majority of these changes reflected decreases in the proportions of various 216	
bacterial genera within the H. pylori-induced atrophic gastritis group, with the only 217	
increase being in Helicobacter itself.  218	
Co-occurrence networks were more complicated in H. pylori-induced atrophic 219	
gastritis patients compared to those subjects who had H. pylori-induced gastritis 220	
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(Figs 5B &D). Clear negative relationships were observed between Helicobacter and 221	
genera such as Streptococcus, whilst Campylobacter, Prevotella, Haemophilus and 222	
Veillonella were amongst the most well-connected and influential bacteria observed 223	
in the stomachs of H. pylori atrophic gastritis patients (Fig 5 and Table S2B). 224	
Predicted pathway analysis showed that several pathways were under-represented 225	
in the H. pylori-induced atrophic gastritis group, including succinate dehydrogenase 226	
(Table S3). Over-represented pathways included fumarate reductase (Table S3).  227	
 228	
Normal stomach versus autoimmune atrophic gastritis 229	
Streptococcaceae (38%) were the most dominant group identified in the stomachs of 230	
patients who had autoimmune atrophic gastritis, followed by Prevotellaceae (9%), 231	
Flavobacteriaceae (7%), Campylobacteraceae (7%), Enterobacteriaceae (5%) and 232	
Pasteurellaceae (5%). The stomachs of autoimmune atrophic gastritis patients 233	
contained a higher proportion of Streptococcaceae than all other patient groups (Fig 234	
3) and were the only samples that showed complete loss or gain of bacteria rather 235	
than simply changes in bacterial proportions (Fig 4D). For example, the stomachs of 236	
autoimmune atrophic gastritis patients were colonised by Gemella and Bosea unlike 237	
any other patient group. Alterations in the relative proportions of other bacteria were 238	
also found in the stomachs of patients with autoimmune atrophic gastritis. These 239	
included increases in the proportions of Streptococcus, Campylobacter and 240	
Haemophilus (Table S1).    241	
Few co-occurrence networks were identified, presumably due to the dominance of 242	
Streptococcaceae, although Stenotrophomonas and Delftia; and Selenomonas and 243	
Pseudomonas showed strong positive correlations (Fig 5D and Table S2B). 244	
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Predicted pathway analysis suggested that several pathways were over- or under-245	
represented in the stomachs of patients who had autoimmune atrophic gastritis 246	
(table S3).  247	
 248	
H. pylori gastritis versus H. pylori-induced atrophic gastritis 249	
We investigated whether the microbiota in the stomachs of patients who had H. 250	
pylori-induced atrophic gastritis (which were likely to be hypochlorhydric as indicated 251	
by hypergastrinaemia) differed from that in patients who had H. pylori gastritis, 252	
normal gastric acid secretion and normogastrinaemia. No significant differences 253	
were identified at the genus level. However, several OTUs belonging to H. pylori 254	
were found more frequently in the H. pylori-induced atrophic gastritis group, possibly 255	
suggesting the presence of particular strains within this group (Table S4A). 256	
Interestingly, only two other OTUs differed in abundance between these groups, 257	
Streptococcus mitis and Neisseria mucosa. However, these did not remain 258	
significant once H. pylori was removed from the analysis. This suggests that the 259	
presence of atrophy does not result in extensive changes to bacterial communities in 260	
the stomach relative to the simple presence of H. pylori, but may result in specific 261	
differences in individual bacterial strains.  262	
 263	
Comparisons between the gastric microbiota of individuals with 264	
hypochlorhydria of different aetiologies 265	
Patients with H. pylori-induced atrophic gastritis and those receiving PPIs had similar 266	
fasting serum gastrin concentrations (median 100pM and 140pM respectively), 267	
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possibly suggesting similar degrees of hypochlorhydria (although H. pylori infection 268	
may have directly contributed to the hypergastrinaemia in the former group). In 269	
contrast patients with autoimmune atrophic gastritis were associated with higher 270	
fasting serum gastrin concentrations (median 800pM; Table 1). No direct association 271	
between fasting serum gastrin concentration and bacterial taxa was observed 272	
between the different groups (PERMANOVA Unifrac P=0.512, weighted Unifrac 273	
P=0.721 and Bray-Curtis P=0.556).  This is reflected in the evidence that patients 274	
with H. pylori-induced atrophic gastritis and those receiving PPIs exhibited marked 275	
differences in 16S rRNA microbiota profiles, co-occurrence networks and predicted 276	
pathways, despite similar gastrin levels. And that patients with autoimmune atrophic 277	
gastritis showed similarities to individuals with H. pylori-induced atrophic gastritis by 278	
predicted pathway analysis, despite markedly different serum gastrin concentrations 279	
(Table S3).  280	
Samples from patients with autoimmune atrophic gastritis contained significantly 281	
more Streptococci than all other groups (Fig 3 & Table S1). Streptococcus did not 282	
appear to be similarly increased in H. pylori-induced atrophic gastritis; this may have 283	
been due to the negative relationship observed between Helicobacter and 284	
Streptococcus identified in co-occurrence networks (Fig 5C).  285	
Gastric biopsies from patients with autoimmune atrophic gastritis and those on PPIs 286	
both showed greater bacterial diversity than was observed in the stomachs of 287	
patients with H. pylori-induced atrophic gastritis (Fig 2). At the genus level, patients 288	
with autoimmune atrophic gastritis showed significant increases in Tannerella, 289	
Dorea, Streptococcus, Fusobacterium and Campylobacter compared to the patients 290	
with H. pylori-induced atrophic gastritis (Table S4B). The stomachs of PPI-treated 291	
patients also contained significantly higher proportions of Fusobacterium and 292	
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Campylobacter than the stomachs of H. pylori-induced atrophic gastritis patients. 293	
Furthermore, patients receiving PPI treatment showed significantly higher 294	
proportions of Flavisolibacter and Dermacoccus in their stomachs than autoimmune 295	
atrophic gastritis patients, but significantly less Paludibacter, Granulicatella, 296	
Streptococcus, and Neisseria. 297	
Patients who had atrophic gastritis due to H. pylori or an autoimmune aetiology both 298	
showed over-representation of several mutual pathways compared to controls (Table 299	
S3). However, differences between the two groups were also observed. For 300	
example, glucose-6-phosphate 1−dehydrogenase and	D−lactate dehydrogenase 301	
pathways were over-represented in the stomachs of patients who had H. pylori-302	
induced atrophic gastritis compared to those who had autoimmune atrophic gastritis 303	
(Table S3).  304	
  305	
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DISCUSSION 306	
Gastric samples obtained from subjects who had a normal stomach, no evidence of 307	
H. pylori infection and normogastrinaemia had the highest levels of microbial 308	
diversity. This is consistent with other reports of healthy populations showing more 309	
microbial diversity[15-17]. These samples also contained the greatest proportion of 310	
Prevotellaceae (23%) which corroborates previous research that reported normal 311	
stomachs contained 37% Prevotella, reducing to 28% in dyspeptic patients[18]. In 312	
general, the microbiota, co-occurrence networks and predicted pathways in samples 313	
from PPI-treated patients were similar to those in normal stomachs. This agrees with 314	
other reports that PPIs do not significantly influence the gastric microbiota[19, 20]. At 315	
the OTU level however, samples from PPI-treated patients contained significantly 316	
more Streptococcus. This has also been observed in gastric[20] and faecal samples 317	
from twins discordant for PPI use[21]. 318	
H. pylori gastritis, and to some extent H. pylori-induced atrophic gastritis samples 319	
were dominated by H. pylori. This observation may have been exacerbated by our 320	
use of RNA as opposed to DNA for sequencing, unlike many other publications. 321	
When these two techniques were directly compared, H. pylori abundance was found 322	
to be 19.9 times higher in RNA compared to DNA from gastric fluid samples, and 323	
was also more dominant in biopsies than gastric fluid[19, 22]. The use of RNA 324	
ensured that only viable bacteria were included in the analysis, giving a better 325	
indication of the taxa that are likely to be influencing the gastric environment. H. 326	
pylori colonisation was associated with a decrease in gastric bacterial diversity, and 327	
dominance of this organism, which is highly adapted to the gastric environment, has 328	
also been reported previously[6, 23, 24].  329	
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The majority of changes observed in H. pylori gastritis and H. pylori-induced atrophic 330	
gastritis samples were due to reductions in non-H. pylori bacteria. H. pylori-induced 331	
atrophic gastritis samples showed complex co-occurrence networks, unlike H. pylori 332	
gastritis which showed few connections, presumably related to the dominance of H. 333	
pylori itself in those samples. Campylobacter, Prevotella, Haemophilus and 334	
Veillonella were amongst the most influential genera in H. pylori-induced atrophic 335	
gastritis samples. These bacteria have been previously identified in oral and gastric 336	
samples[22].The only differences found between the two H. pylori patient groups at 337	
the OTU level were increased abundances of specific H. pylori OTUs (possibly 338	
suggesting specific bacterial strains) and increased proportions of Streptococcus 339	
mitis and Neisseria mucosa in the atrophic group. The former species and latter 340	
genus have been identified from oral microbiota as potential biomarkers for 341	
pancreatic cancer[25]. Neisseria has been shown to produce large amounts of 342	
alcohol dehydrogenase, which produces the carcinogen acetaldehyde, and along 343	
with H. pylori’s high production of this enzyme, may also contribute to gastric 344	
carcinogenesis[26]. Some strains of Streptococcaceae have previously been shown 345	
to affect the outcomes of H. pylori infection. For example, S. mitis induces a coccoid 346	
state in H. pylori[27] and this may lead to unsuccessful antibiotic treatment and false 347	
negative diagnostic test results. Moreover, this coccoid form has been suggested to 348	
be more associated with gastric adenocarcinoma development than the spiral 349	
form[28, 29].  350	
The stomachs of patients with autoimmune atrophic gastritis (who probably had the 351	
most profound reductions in acid secretion, as suggested by higher fasting serum 352	
gastrin concentrations), showed high bacterial diversity. Samples from this group 353	
also showed significantly higher proportions of Streptococcus than any of the other 354	
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groups. They also contained Ruminococcus and Gemella unlike any other patient 355	
group except H. pylori-induced atrophic gastritis, although they did not contain 356	
genera such as Arthrobacter, Cupriavidus and Sneathia. Therefore, bacterial 357	
communities were both lost and gained in this condition. Co-occurrence networks 358	
appeared to be disrupted by the overabundance of Streptococcaceae resulting in 359	
few connections.  360	
The microbial profiles in the stomachs of patients with H. pylori-induced atrophic 361	
gastritis and autoimmune atrophic gastritis were quite different. In addition, pathways 362	
such as glucose-6-phosphate 1−dehydrogenase and D−lactate dehydrogenase were 363	
over-represented in the stomachs of patients with H. pylori-induced atrophic gastritis 364	
compared to autoimmune atrophic gastritis. Overexpression of these pathways has 365	
been associated with poorer prognoses in gastric cancer[30, 31]. Conversely, 366	
several other metabolic pathways such as fumarate reductase were increased in 367	
representation in patients with both autoimmune and H. pylori associated atrophic 368	
gastritis. Fumarate reductase is involved in the metabolism of some bacteria and is 369	
essential for colonisation by H. pylori in the mouse stomach[32-34]. Interestingly, 370	
succinate dehydrogenase (which has an opposite action to fumarate reductase) was 371	
found to be decreased in both atrophic gastritis groups compared to both the normal 372	
and PPI-treated samples. Lower levels of succinate dehydrogenase have previously 373	
been found in gastrointestinal tumours and parietal cells[35, 36].	PPI-treated patients 374	
showed more similarities in microbial diversity and abundance to the patients who 375	
had autoimmune atrophic gastritis, than to the patients who had H. pylori-induced 376	
atrophic gastritis.  377	
The strengths of this study are the relatively large cohort of patients and the 378	
subsequently high numbers of samples sequenced. Weaknesses of the study 379	
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include a lack of dietary information recorded for the patients, and although patient 380	
groups had similar age and gender profiles it was not possible to specifically 381	
age/gender match them as priority was given to the strict criteria used to allocate 382	
patients to groups. Future studies are also needed to elucidate and confirm the 383	
predicted pathway analysis.  384	
Conclusion 385	
Our findings indicate that H. pylori colonisation and hypochlorhydria (other than that 386	
which was caused by PPI treatment) result in changes in gastric bacterial abundance 387	
and only rarely in loss/gain of bacteria. PPI treatment did not significantly alter the 388	
gastric microbiota from that of a normal stomach, despite serum gastrin 389	
concentrations being comparable to those found in patients with H. pylori-induced 390	
atrophic gastritis. Microbial patterns were not found to correlate with gastrin levels, 391	
although it should be noted that factors including H. pylori infection status may have 392	
confounded this relationship. Autoimmune atrophic gastritis resulted in a different, 393	
more diverse microbial pattern than that observed in the stomachs of patients who 394	
had H. pylori-induced atrophic gastritis. This may be due to differences in acid 395	
secretion between these conditions or other factors such as different immune 396	
profiles. Several biochemical pathways were represented in similar fashions in both 397	
atrophic gastritis groups. In particular, gastric-atrophy was associated with changes 398	
in the citric acid cycle (biochemical pathway that is known to be associated with 399	
gastric carcinogenesis) and our findings suggest that the microbiota may be an 400	
important contributor to this. The development of gastric cancer is multifactorial, and 401	
data from the present study suggest that the non-H. pylori	microbiota may be a 402	
participating factor.  403	
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MATERIALS AND METHODS 404	
Ethics 405	
Acquisition of the biopsies used in this study was approved by Liverpool 406	
(08/H1005/37) and Cambridge East (10/H0304/51) Research Ethics Committees as 407	
previously described[37, 38]. All patients gave written informed consent.  408	
Patients 409	
One hundred gastric biopsy samples in 5 different groups were selected from a 410	
cohort of 1400 prospectively recruited patients who underwent diagnostic upper 411	
gastrointestinal endoscopy at Royal Liverpool University Hospital[37] and from 8 412	
patients with type I gastric NETs who had been recruited to a clinical trial[38, 39] 413	
(Table 1). The patients in the 1400 cohort had the following characteristics: Females 414	
57.5%, median age 60 years with an interquartile range 48-70 years and 98.4% were 415	
Caucasian. Overall more than half the cohort (52.3%) reported PPI use, 21.8% were 416	
positive for H. pylori infection by histology, and 43.3% were positive by serology. 417	
Patients were selected from this cohort according to the criteria described below and 418	
that are outlined in Table 1. None of the selected patients were taking PPIs, except 419	
those in the PPI treated group. In some patient groups (e.g. those with H. pylori 420	
associated atrophy and autoimmune atrophic gastritis) all samples which matched 421	
the inclusion criteria were sequenced, but for other groups (e.g. normal and PPI 422	
treated groups), subjects were chosen for inclusion based on the availability of tissue 423	
(as biopsy samples from this cohort have also been used for other studies). 424	
 425	
 426	
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Table 1. Summary of patient group characteristics  427	
	428	
ND= Not done 429	
IQR= Interquartile range, 25% and 75% 430	
 431	
Patients in the normal stomach group had a normal endoscopy, no evidence of H. 432	
pylori infection by histology, rapid urease test or serology, were not taking a PPI and 433	
were normogastrinaemic. Patients belonging to the H. pylori gastritis group were 434	
positive for H. pylori by rapid urease test, histology and serology, had no histological 435	
evidence of atrophic gastritis, were not taking a PPI and were normogastrinaemic. 436	
Patients in the H. pylori-induced atrophic gastritis group showed histological 437	
evidence of corpus atrophic gastritis and/or intestinal metaplasia, had no dysplasia 438	
or cancer, were positive for H. pylori by serology, were not taking a PPI and were 439	
hypergastrinaemic.  Six out of the 23 patients in this group were also H. pylori 440	
positive by urease test and/or histology. Details of histological Sydney scoring [40] 441	
can be seen in supplementary figure 4.	Patients in both H. pylori infected groups 442	
showed higher scores in both antrum and corpus than patients in the normal 443	
stomach and PPI treated groups. Patients in the autoimmune atrophic gastritis group 444	
	
	 Group	
Total	
no.	of	
samples	
Number	
of	
females	
Age	(years)	
	 BMI	 H.	pylori	
serology	
+ve	
H.	pylori	
histology	
/urease	
+ve	
PPI	
use	
Atrophic	
gastritis	
Serum	gastrin	
(pM)	 Anti	
GPC/IF	
antibody	Median	 IQR	 Median	 IQR	 Median	 IQR	
1	 Normal	 20	 13	 46	
30.5-
58.7	 24.5	
21.2-
26.8	 0	 0	 -	 -	 22.5	
17.5-
28.5	 -	or	ND	
2	 PPI	treated	 19	 13	 60	
46-
67	 28.5	
26.1-
33.2	 0	 0	 +	 -	 140	
94-
200	 -	or	ND	
3	
H.	pylori	
gastritis	
	
22	 11	 57.5	
	
47.7-
64	 27.4	
	
23.3-
27.1	
	
22	
	
22	 -	
	
-	
	
21.5	
	
17.4-
28	
	
-	or	ND	
4	
H.	pylori	
atrophy	
	
23	 15	 65	
	
55-
72	 25.9	
	
24.6-
31.9	
	
23	
	
6	 -	
	
+	
	
100	
	
64-
260	
	
-	or	ND	
5	
Autoimmune	
atrophy	
	
11	 6	 67	
	
60-
76	 28.6	
	
23.7-
35	
	
2	
	
0	 -	
	
+	
	
800	
	
470-
1050	
	
+	
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had histological evidence of atrophic gastritis, no evidence of H. pylori infection by 445	
rapid urease test or histology, positive anti-gastric parietal cell and/or intrinsic factor 446	
antibodies, were markedly hypergastrinaemic and 8 out of 11 also had grade 1 type I 447	
gastric NETs. Patients in the PPI-treated group were currently taking PPIs, had no 448	
evidence of H. pylori infection by serology, rapid urease test or histology, had no 449	
histological evidence of atrophic gastritis and were hypergastrinaemic (suggesting 450	
significant hypochlorhydria).  451	
Samples 452	
At least two biopsies per site were obtained from the gastric antrum and corpus for 453	
histopathology. Eight additional corpus biopsies were stored in RNA later 454	
immediately after removal and were extracted using a modified Tri- reagent 455	
protocol[41]. Briefly, samples were thawed and separated from RNA later, before 456	
being homogenised in Tri-Reagent® (Sigma-Aldrich, Gillingham, UK). Chloroform 457	
was added and the resulting clear aqueous layer was combined with isopropanol 458	
before centrifugation to produce a precipitated RNA pellet. This was washed with 459	
75% and 100% ice cold ethanol before being allowed to dry and then resuspended in 460	
diethylpyrocarbonate (DEPC)-treated water (Sigma-Aldrich, Gillingham, UK). RNA 461	
was stored in ethanol at -80°C. Ethanol was removed and pellets were resuspended 462	
in DEPC-water prior to reverse transcription.  463	
Gastrin assays 464	
Serum gastrin concentrations were measured by radioimmunoassay (RIA) as 465	
previously described[42, 43]. Fasting serum gastrin concentrations were all <40pM in 466	
normogastrinaemic subjects and >40pM	(with the majority >100pM) in 467	
hypergastrinaemic subjects.  468	
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Reverse Transcription  469	
Samples and random primers were denatured together for 5 minutes at 65°C before 470	
Proto reaction mix and Proto enzyme from a ProtoScript® II First Strand cDNA 471	
Synthesis kit (NEB, E6560L) were added. Samples were then incubated at 25°C for 472	
5 minutes, 42°C for 20 minutes, and 80°C for 5 minutes. Newly synthesised cDNA 473	
was then measured using a Qubit high sensitivity assay (ThermoFisher Ltd, Paisley, 474	
UK). 475	
16S rRNA Sequencing 476	
The 16S rRNA gene was targeted using V1-V2 (27F and 388R) primers[44] with 477	
slight modifications: forward primer 5'ACACTCTTTCCCTACACGACGC 478	
TCTTCCGATCTNNNNNAGAGTTTGATCMTGGCTCAG’3, reverse primer 479	
5’GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGCTGCCTCCCGTAGGAGT’480	
3. Primers were validated using a mock community described in supplementary 481	
methods. The following cycling conditions were used: initial denaturation 94°C for 5 482	
minutes, followed by 10 cycles of denaturation at 98°C for 20 seconds, annealing at 483	
60°C for 15 seconds, and elongation at 72°C for 15 seconds, followed by a final 484	
elongation step of 72°C for 1 minute. PCR amplicons were purified to remove excess 485	
primers, nucleotides, salts, and enzymes using the Agencourt® AMPure® XP 486	
system (Beckman Coulter Ltd, High Wycombe, UK). Purified amplicons were used in 487	
a second PCR reaction with the same conditions except with 20 cycles. This second 488	
step was used to add dual index barcodes. The PCR amplicons were purified as 489	
above. All PCR reactions used Kapa HiFi HotStartStart 2× master mix (Anachem 490	
Ltd, Bedfordshire, UK) and all primers were used at 10µM. Amplicon sizes were 491	
checked using a fragment analyser (Advanced Analytical, Ankeny, USA) and size 492	
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selection was performed using a Pippin prep (Sage Science, Beverly, USA). The 493	
quantity and quality of the samples in the final libraries were checked using a SYBR 494	
Green qPCR assay and the Illumina Library Quantification kit (Kapa) on a Roche 495	
Light Cycler LC480II, according to the manufacturer's instructions. 496	
Prior to loading samples onto the MiSeq, PhiX was added (10-15%) to increase 497	
diversity, and samples were then denatured with NaOH according to the Illumina 498	
MiSeq protocol. ssDNA library fragments were diluted to a final concentration of 499	
8pM. 600μl of ssDNA library was loaded into a MiSeq Reagent Cartridge and a 500–500	
cycle PE kit v2 was used. Paired-end sequencing was performed according to the 501	
manufacturer’s instructions (Illumina, SanDiego, CA, USA). Sequence analysis 502	
methodology is described in the supplementary methods. Reads were submitted to 503	
EBI short-read archive accession-PRJEB21104. 504	
Statistical analysis  505	
Details are described in the supplementary methods.506	
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FIGURE LEGENDS 693	
Table 1. Summary of patient group characteristics. ND = Not done, IQR = 694	
Interquartile range, 25% and 75%. 695	
Figure 1. (A) Median fasting serum gastrin concentrations (pM) in patient groups. 696	
Kruskal-Wallis test with Dunn’s comparison, plotted using Tukey’s method *=P<0.05, 697	
and ****=P<0.0001 vs control. (B) Mean number of OTUs identified within each 698	
patient group, 1-way ANOVA and Tukey’s multiple comparison test *=P<0.05, 699	
**=P<0.01, Control vs Autoimmune atrophic gastritis P=0.059, Control vs Neg 700	
P=0.061 and Hp-induced atrophic gastritis vs Neg P=0.059.  701	
Figure 2. Five different diversity indices of human gastric microbiota (Fisher alpha: 702	
parametric index of diversity that models species as logseries distribution; Pielou’s 703	
evenness: how close in numbers each species is; Richness: number of species per 704	
sample; Shannon: a commonly used index to characterise species diversity; and 705	
Simpson: which takes into account the number of species present, as well as their 706	
relative abundance). Pair-wise ANOVA was performed between different groups and 707	
if significant (P<0.001), the p-values have been drawn on top. Atrophy=H. pylori 708	
associated atrophy, Auto=autoimmune atrophic gastritis, Control=normal stomach, 709	
HP Gast=H. pylori associated gastritis, PPI=proton pump inhibitor and Neg= 710	
extraction control. 711	
Figure 3. Relative abundances of taxa found within (A) groups and (B) individual 712	
human gastric biopsies. Hp=H. pylori, IM=intestinal metaplasia, IM+At=intestinal 713	
metaplasia and atrophy, PPI=proton pump inhibitor, EC=extraction controls (one of 714	
the EC samples was included in a run with more H. pylori dominant samples), 715	
H=H2O and M=mock community (which showed consistent findings on two runs as 716	
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shown). All H. pylori atrophic gastritis samples were positive for H. pylori by serology, 717	
+ indicates whether these samples were also positive by histology/rapid urease test. 718	
Autoimmune atrophic gastritis samples recorded as ‘s’ were also positive for H. pylori 719	
by serology. 720	
Figure 4. Nonmetric distance scaling (NMDS) demonstrating clustering of patient 721	
groups using (A) unweighted Unifrac distance (pair-wise distance between samples 722	
is calculated as a normalised difference in cumulative branch lengths of the 723	
observed OTUs for each sample on the phylogenetic tree without taking into account 724	
their abundances in samples), (B) Bray-Curtis distance (abundance of OTUs alone 725	
and not considering the phylogenetic distance) and (C) weighted Unifrac 726	
(unweighted unifrac distance weighted by abundances of OTUs). Serum gastrin 727	
concentration indicated by size of each point. Ellipses represent 95% CI of standard 728	
error for a given group. Dotted ellipses represent the 95% CI of standard error when 729	
H. pylori were removed from the analysis. Atrophy=H. pylori associated atrophic 730	
gastritis, Auto=autoimmune atrophic gastritis, Control=normal, HP Gastr=H. pylori 731	
associated gastritis and PPI=proton pump inhibitor. PERMANOVA (distances against 732	
groups) suggests significant differences (P<0.001 for all three distances) in microbial 733	
community explaining the following variations (R2) between groups: 10% (8.6% 734	
without H. pylori when using Unweighted Unifrac; 58% (14.5% without H. pylori) 735	
when using Weighted Unifrac; and 15% when using Bray-Curtis distance. No 736	
significant explanation was observed (P>0.05) for age, BMI, or serum gastrin 737	
concentration in the PERMANOVA test. (D) Data from betadisper plots (a mean to 738	
compare the spread/variability of samples for different groups) representing 739	
difference in distances (Bray-Curtis, Unweighted and weighted Unifrac) of group 740	
members from the centre/mean of individual groups after obtaining a reduced-order 741	
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representation of abundance table using Principle Coordinate Analysis. The pair-742	
wise differences in distances from group centre/mean were then subjected to 743	
ANOVA and if significant (P<0.001), the p-values were drawn on top.  744	
Figure 5. Co-occurrence network analysis between different genera (OTUs collated 745	
together at genus level) when considering samples for (A) normal stomach, (B) H. 746	
pylori gastritis, (C) H. pylori-induced atrophic gastritis and (D) autoimmune atrophic 747	
gastritis. The genera were connected (Blue: positive correlation; Red: negative 748	
correlation) when the pair-wise correlation values were significant (P.adj<0.05) after 749	
adjusting the P values for multiple comparisons. Furthermore, subcommunity 750	
detection was performed by placing the genera in the same subcommunity 751	
(represented by colour of nodes) when many links were found at correlation values 752	
>0.75 between members of the subcommunity. The size of the nodes represent the 753	
degree of connections.  754	
 755	
Supplementary Figure and Table Legends 756	
Figure S1. Relative abundances of taxa found within human gastric biopsies after 757	
removal of Helicobacteraceae. Hp=H. pylori, IM=intestinal metaplasia, 758	
IM+At=intestinal metaplasia and atrophy, PPI=proton pump inhibitor. All H. pylori 759	
atrophy samples were positive for H. pylori by serology. 760	
Figure S3. Co-occurrence network analysis between different genera (OTUs 761	
collated together at genus level) when considering samples for (A) PPI. The genera 762	
were connected (Blue: positive correlation; Red: negative correlation) when the pair-763	
wise correlation values were significant (P.adj<0.05) after adjusting the P values for 764	
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multiple comparisons. Furthermore, subcommunity detection was performed by 765	
placing the genera in the same subcommunity (represented by colour of nodes) 766	
when many links were found at correlation values >0.75 between members of the 767	
subcommunity. The size of the nodes represent the degree of connections (B) 768	
network-wide statistics by degree, closeness, betweenness and eigenvalue centrality 769	
for H. pylori atrophic gastritis cases. The nodes (coloured with respect to 770	
subcommunity they are part of) were placed on concentric circles with values 771	
increasing from center to the periphery. A high betweenness for a node suggests 772	
many connections, whereas a high eigenvalue centrality suggests that those 773	
connections, in turn, are all well connected. On average a high betweenness and at 774	
the same time low eigenvalue centrality for a subcommunity suggests a 775	
keystone/important subcommunity. 776	
Figure S4.  Mean updated Sydney scores in antrum and corpus. Updated Sydney 777	
scores were the sum of the scores for 5 individual parameters each scored 0-3 [40]. 778	
**** p<0.0001 versus control from the same mucosal site by 2-way ANOVA using 779	
Dunnett’s multiple comparison test. 780	
Table S1. Significantly different genera identified between normal stomach samples 781	
and PPI, autoimmune atrophic gastritis, H. pylori-induced atrophic gastritis and H. 782	
pylori gastritis. The most significant species are identified at the top. Differential 783	
expression analysis based on the Negative Binomial (Gamma-Poisson) distribution 784	
and were corrected for multiple comparisons. * indicates a genus no longer 785	
significant when H. pylori was removed from the analysis. 786	
Table S2A. Stable bacterial populations and correlations in PPI patients compared 787	
to other groups (if the correlation between two genera were consistently positive or 788	
	37	
	
negative in different groups). PPI versus H. pylori-induced atrophic gastritis in table 789	
S2B. No significant comparisons were found between PPI and autoimmune atrophic 790	
gastritis groups. 791	
Table S2B. Stable bacterial populations and correlations in H. pylori-induced 792	
atrophic gastritis patients compared to other groups. 793	
Table S3. The top most significant predicted pathways found for each group 794	
comparison. 795	
Table S4A. Significant bacterial species identified between H. pylori atrophic gastritis 796	
and H. pylori gastritis. The most significant species are identified at the top. 797	
Differential expression analysis based on the Negative Binomial (Gamma-Poisson) 798	
distribution. Streptococcus identified by BLAST as S. mitis with 98% coverage, 99% 799	
identity and Neisseria mucosa had 98% coverage and 100% identity. None of these 800	
OTUs remained significant when H. pylori was removed from the analysis.  801	
Table S4B. Significant bacterial genera identified between autoimmune atrophic 802	
gastritis and H. pylori-induced atrophic gastritis. The most significant species are 803	
identified at the top. Differential expression analysis based on the Negative Binomial 804	
(Gamma-Poisson) distribution. NB when H. pylori was removed from the analysis 805	
these genera remained significant, with an additional genus Desulfobulbus also 806	
reaching significance. 807	
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